Despite patients' widespread acknowledgment of their recurring or chronic constipation, their knowledge of prescription and therapy options are low, according to a ne...

After an indefinite commercial delay on its Shire-acquired rare disease drug this spring, Takeda’s yearslong Natpara manufacturing saga is drawing to a close. Th...

In a long-running patent case against pharma giant Novartis, Daiichi Sankyo has secured a key win in the U.S. District Court for the Northern District of California. ...

For COVID-19 antibody drugs in the pandemic world, it’s been life in the fast lane. With the coronavirus rapidly evolving, there is little longevity for finely tuned...

A month ago, Zhejiang Huahai revealed a five-year deal to produce and sell Pfizer’s COVID-19 oral antiviral Paxlovid exclusively in China. Now, not to be outdo...

As Sanofi prepares to release third-quarter results—after a tough summer for its share price—the company says it expects a major boost from exchange rate changes. ...

Age discrimination lawsuits have been cropping up around the industry in recent years, and Eli Lilly is no stranger to such claims. Now, the company is defending agai...

Don’t doubt the biopharma industry’s ability to find ways to circumvent the effects of the Inflation Reduction Act, signed last month by President Joe Biden. B...

When a plaintiff's lawyer in the Johnson & Johnson talc litigation became flustered in a federal appeals hearing on Monday, presiding Judge Thomas Ambro stepped i...

After a potential $40 billion merger between pharma giant Merck & Co. and antibody-drug conjugate (ADC) specialist Seagen reportedly stalled on pricing last month...